The clinical spectrum of laryngeal dystonia includes dystonic cough: observations of a large series.
Identifieur interne : 003F64 ( Ncbi/Curation ); précédent : 003F63; suivant : 003F65The clinical spectrum of laryngeal dystonia includes dystonic cough: observations of a large series.
Auteurs : Susannah Payne [Australie] ; Stephen Tisch ; Ian Cole ; Helen Brake ; Judy Rough ; Paul DarvenizaSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2014.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Botulinum Toxins (therapeutic use), Cough (drug therapy), Cough (etiology), Dystonia (classification), Dystonia (complications), Dystonia (drug therapy), Female, Humans, Laryngeal Diseases (complications), Laryngeal Diseases (drug therapy), Linear Models, Male, Middle Aged, Neurotoxins (therapeutic use), Observation, Retrospective Studies, Severity of Illness Index, Young Adult.
- MESH :
- chemical , therapeutic use : Botulinum Toxins, Neurotoxins.
- classification : Dystonia.
- complications : Dystonia, Laryngeal Diseases.
- drug therapy : Cough, Dystonia, Laryngeal Diseases.
- etiology : Cough.
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Linear Models, Male, Middle Aged, Observation, Retrospective Studies, Severity of Illness Index, Young Adult.
Abstract
Laryngeal dystonia is a movement disorder of the muscles within the larynx, which most commonly manifests as spasmodic dysphonia (SD). Rarer reported manifestations include dystonic respiratory stridor and dyscoordinate breathing. Laryngeal dystonia has been treated successfully with botulinum neurotoxin (BTX) injections since 1984. We reviewed prospectively collected data in a consecutive series of 193 patients with laryngeal dystonia who were seen at St. Vincent's Hospital between 1991 and 2011. Patient data were analyzed in Excel, R, and Prism. Laryngeal dystonia manifested as SD (92.7%), stridor (11.9%), dystonic cough (6.2%), dyscoordinate breathing (4.1%), paroxysmal hiccups (1.6%), and paroxysmal sneezing (1.6%). There were more women (68.4%) than men (31.6%), and the average age at onset was 47 years. A positive family history of dystonia was present in 16.1% of patients. A higher incidence of extra-laryngeal dystonia (ie, torticollis and blepharospasm) and concurrent manifestations of laryngeal dystonia were present in patients with dystonic cough, dyscoordinate breathing, paroxysmal sneezing, and hiccups than in other patients (P = 0.003 and P < 0.0001, respectively). The average starting dose of BTX decreased from 2.3 to 0.5 units between 1991 and 2011. The median treatment rating was excellent across all subgroups. Patients with adductor SD, stridor, extra-laryngeal dystonia and male patients had relatively better treatment outcomes. Technical failures were rare (1.1%). Dysphonia secondary to vocal cord paresis followed 38.7% of treatments. Laryngeal dystonia manifests predominantly as SD, but other manifestations include stridor, dyscoordinate breathing, paroxysmal cough, hiccups, and sneezing. BTX injections are very effective across all subgroups. Severe adverse events are rare.
DOI: 10.1002/mds.25865
PubMed: 24753288
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000535
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000535
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000399
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :003F64
Links to Exploration step
pubmed:24753288Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The clinical spectrum of laryngeal dystonia includes dystonic cough: observations of a large series.</title>
<author><name sortKey="Payne, Susannah" sort="Payne, Susannah" uniqKey="Payne S" first="Susannah" last="Payne">Susannah Payne</name>
<affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Faculty of Medicine, University of New South Wales, Sydney, New South Wales</wicri:regionArea>
<wicri:noRegion>New South Wales</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tisch, Stephen" sort="Tisch, Stephen" uniqKey="Tisch S" first="Stephen" last="Tisch">Stephen Tisch</name>
</author>
<author><name sortKey="Cole, Ian" sort="Cole, Ian" uniqKey="Cole I" first="Ian" last="Cole">Ian Cole</name>
</author>
<author><name sortKey="Brake, Helen" sort="Brake, Helen" uniqKey="Brake H" first="Helen" last="Brake">Helen Brake</name>
</author>
<author><name sortKey="Rough, Judy" sort="Rough, Judy" uniqKey="Rough J" first="Judy" last="Rough">Judy Rough</name>
</author>
<author><name sortKey="Darveniza, Paul" sort="Darveniza, Paul" uniqKey="Darveniza P" first="Paul" last="Darveniza">Paul Darveniza</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24753288</idno>
<idno type="pmid">24753288</idno>
<idno type="doi">10.1002/mds.25865</idno>
<idno type="wicri:Area/PubMed/Corpus">000535</idno>
<idno type="wicri:Area/PubMed/Curation">000535</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000399</idno>
<idno type="wicri:Area/Ncbi/Merge">003F64</idno>
<idno type="wicri:Area/Ncbi/Curation">003F64</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The clinical spectrum of laryngeal dystonia includes dystonic cough: observations of a large series.</title>
<author><name sortKey="Payne, Susannah" sort="Payne, Susannah" uniqKey="Payne S" first="Susannah" last="Payne">Susannah Payne</name>
<affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Faculty of Medicine, University of New South Wales, Sydney, New South Wales</wicri:regionArea>
<wicri:noRegion>New South Wales</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tisch, Stephen" sort="Tisch, Stephen" uniqKey="Tisch S" first="Stephen" last="Tisch">Stephen Tisch</name>
</author>
<author><name sortKey="Cole, Ian" sort="Cole, Ian" uniqKey="Cole I" first="Ian" last="Cole">Ian Cole</name>
</author>
<author><name sortKey="Brake, Helen" sort="Brake, Helen" uniqKey="Brake H" first="Helen" last="Brake">Helen Brake</name>
</author>
<author><name sortKey="Rough, Judy" sort="Rough, Judy" uniqKey="Rough J" first="Judy" last="Rough">Judy Rough</name>
</author>
<author><name sortKey="Darveniza, Paul" sort="Darveniza, Paul" uniqKey="Darveniza P" first="Paul" last="Darveniza">Paul Darveniza</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Botulinum Toxins (therapeutic use)</term>
<term>Cough (drug therapy)</term>
<term>Cough (etiology)</term>
<term>Dystonia (classification)</term>
<term>Dystonia (complications)</term>
<term>Dystonia (drug therapy)</term>
<term>Female</term>
<term>Humans</term>
<term>Laryngeal Diseases (complications)</term>
<term>Laryngeal Diseases (drug therapy)</term>
<term>Linear Models</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neurotoxins (therapeutic use)</term>
<term>Observation</term>
<term>Retrospective Studies</term>
<term>Severity of Illness Index</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins</term>
<term>Neurotoxins</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Dystonia</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Dystonia</term>
<term>Laryngeal Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cough</term>
<term>Dystonia</term>
<term>Laryngeal Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cough</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Female</term>
<term>Humans</term>
<term>Linear Models</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Observation</term>
<term>Retrospective Studies</term>
<term>Severity of Illness Index</term>
<term>Young Adult</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Laryngeal dystonia is a movement disorder of the muscles within the larynx, which most commonly manifests as spasmodic dysphonia (SD). Rarer reported manifestations include dystonic respiratory stridor and dyscoordinate breathing. Laryngeal dystonia has been treated successfully with botulinum neurotoxin (BTX) injections since 1984. We reviewed prospectively collected data in a consecutive series of 193 patients with laryngeal dystonia who were seen at St. Vincent's Hospital between 1991 and 2011. Patient data were analyzed in Excel, R, and Prism. Laryngeal dystonia manifested as SD (92.7%), stridor (11.9%), dystonic cough (6.2%), dyscoordinate breathing (4.1%), paroxysmal hiccups (1.6%), and paroxysmal sneezing (1.6%). There were more women (68.4%) than men (31.6%), and the average age at onset was 47 years. A positive family history of dystonia was present in 16.1% of patients. A higher incidence of extra-laryngeal dystonia (ie, torticollis and blepharospasm) and concurrent manifestations of laryngeal dystonia were present in patients with dystonic cough, dyscoordinate breathing, paroxysmal sneezing, and hiccups than in other patients (P = 0.003 and P < 0.0001, respectively). The average starting dose of BTX decreased from 2.3 to 0.5 units between 1991 and 2011. The median treatment rating was excellent across all subgroups. Patients with adductor SD, stridor, extra-laryngeal dystonia and male patients had relatively better treatment outcomes. Technical failures were rare (1.1%). Dysphonia secondary to vocal cord paresis followed 38.7% of treatments. Laryngeal dystonia manifests predominantly as SD, but other manifestations include stridor, dyscoordinate breathing, paroxysmal cough, hiccups, and sneezing. BTX injections are very effective across all subgroups. Severe adverse events are rare.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003F64 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 003F64 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:24753288 |texte= The clinical spectrum of laryngeal dystonia includes dystonic cough: observations of a large series. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:24753288" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
This area was generated with Dilib version V0.6.23. |